Pericarditis Caused by
Journal
Case reports in critical care
ISSN: 2090-6420
Titre abrégé: Case Rep Crit Care
Pays: United States
ID NLM: 101598416
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
09
2020
accepted:
16
02
2021
entrez:
5
4
2021
pubmed:
6
4
2021
medline:
6
4
2021
Statut:
epublish
Résumé
Sepsis and septic shock are still life-threatening diseases with a high mortality rate. We report a complex case of peritonitis with pericarditis and acute liver failure caused by septic shock. Potentially hepatotoxic antibiotic therapy levels were monitored using the liver maximum capacity (LiMAx®) test, and standard treatment was supplemented by adjunctive hemoadsorption with CytoSorb®. This case shows how complex infectious diseases with an atypical infectious focus resulting in septic shock can be successfully treated. A combination of antimicrobial (tigecycline and caspofungin) and long-term adjunctive hemoadsorption therapy was administered while hepatotoxic antibiotic medication was monitored by liver function testing.
Sections du résumé
BACKGROUND
BACKGROUND
Sepsis and septic shock are still life-threatening diseases with a high mortality rate. We report a complex case of peritonitis with pericarditis and acute liver failure caused by septic shock. Potentially hepatotoxic antibiotic therapy levels were monitored using the liver maximum capacity (LiMAx®) test, and standard treatment was supplemented by adjunctive hemoadsorption with CytoSorb®.
CONCLUSIONS
CONCLUSIONS
This case shows how complex infectious diseases with an atypical infectious focus resulting in septic shock can be successfully treated. A combination of antimicrobial (tigecycline and caspofungin) and long-term adjunctive hemoadsorption therapy was administered while hepatotoxic antibiotic medication was monitored by liver function testing.
Identifiants
pubmed: 33815848
doi: 10.1155/2021/8824050
pmc: PMC7987411
doi:
Types de publication
Case Reports
Langues
eng
Pagination
8824050Informations de copyright
Copyright © 2021 Thomas Köhler et al.
Déclaration de conflit d'intérêts
TK has received lecture fees from the company Cytosorbent Europe. The other authors declare that they have no conflicts of interest.
Références
Crit Care. 2013 Oct 31;17(5):R259
pubmed: 24172237
BMC Anesthesiol. 2018 Jun 20;18(1):71
pubmed: 29925334
J Clin Gastroenterol. 2008 Sep;42(8):956-8
pubmed: 18385605
J Intensive Care Soc. 2015 Aug;16(3):257-264
pubmed: 28979423
Crit Care. 2017 Mar 27;21(1):74
pubmed: 28343448
Ann Thorac Surg. 2019 Jul;108(1):45-51
pubmed: 30684482
Front Immunol. 2018 Jun 01;9:1233
pubmed: 29910817
Nat Rev Gastroenterol Hepatol. 2016 Mar;13(3):131-49
pubmed: 26837712
J Intensive Care Soc. 2019 May;20(2):174-181
pubmed: 31037112
BJS Open. 2018 Jun 14;2(5):301-309
pubmed: 30263981
Crit Care. 2015 Mar 13;19:84
pubmed: 25881576
Int J Artif Organs. 2019 Feb;42(2):57-64
pubmed: 30545255
Blood Purif. 2019;47(1-3):10-15
pubmed: 30219813
Intensive Care Med. 2019 Feb;45(2):236-239
pubmed: 30446798
Infection. 2017 Dec;45(6):737-779
pubmed: 28702763
Eur Heart J. 2015 Nov 7;36(42):2921-2964
pubmed: 26320112
J Fungi (Basel). 2018 Dec 10;4(4):
pubmed: 30544724
Case Rep Crit Care. 2019 Dec 26;2019:5362514
pubmed: 31949955
Int J Artif Organs. 2019 May;42(5):263-268
pubmed: 30919732
J Infect Dev Ctries. 2015 Jul 30;9(7):780-4
pubmed: 26230130
Infect Drug Resist. 2015 Jul 24;8:217-30
pubmed: 26244026
J Antimicrob Chemother. 2009 Nov;64(5):929-37
pubmed: 19706668